Avid Bioservices Inc (CDMO)
8.42
+0.17
(+2.06%)
USD |
NASDAQ |
May 06, 16:00
8.425
0.00 (0.00%)
Pre-Market: 20:00
Avid Bioservices SG&A Expense (Quarterly): 6.382M for Jan. 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
January 31, 2024 | 6.382M |
October 31, 2023 | 6.557M |
July 31, 2023 | 6.263M |
April 30, 2023 | 7.559M |
January 31, 2023 | 7.107M |
October 31, 2022 | 6.831M |
July 31, 2022 | 6.382M |
April 30, 2022 | 5.915M |
January 31, 2022 | 5.818M |
October 31, 2021 | 5.033M |
July 31, 2021 | 4.46M |
April 30, 2021 | 5.055M |
January 31, 2021 | 4.018M |
October 31, 2020 | 4.166M |
July 31, 2020 | 3.825M |
April 30, 2020 | 3.528M |
January 31, 2020 | 2.996M |
October 31, 2019 | 3.534M |
July 31, 2019 | 4.459M |
April 30, 2019 | 3.573M |
January 31, 2019 | 3.242M |
October 31, 2018 | 2.816M |
July 31, 2018 | 3.215M |
April 30, 2018 | 4.183M |
January 31, 2018 | 4.824M |
Date | Value |
---|---|
October 31, 2017 | 3.596M |
July 31, 2017 | 3.853M |
April 30, 2017 | 4.477M |
January 31, 2017 | 4.365M |
October 31, 2016 | 4.984M |
July 31, 2016 | 5.06M |
April 30, 2016 | 4.065M |
January 31, 2016 | 4.524M |
October 31, 2015 | 4.416M |
July 31, 2015 | 4.899M |
April 30, 2015 | 5.188M |
January 31, 2015 | 4.325M |
October 31, 2014 | 4.295M |
July 31, 2014 | 4.883M |
April 30, 2014 | 4.361M |
January 31, 2014 | 4.563M |
October 31, 2013 | 4.016M |
July 31, 2013 | 4.334M |
April 30, 2013 | 3.665M |
January 31, 2013 | 3.112M |
October 31, 2012 | 3.44M |
July 31, 2012 | 2.917M |
April 30, 2012 | 3.091M |
January 31, 2012 | 2.71M |
October 31, 2011 | 2.732M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.996M
Minimum
Jan 2020
7.559M
Maximum
Apr 2023
5.257M
Average
5.055M
Median
Apr 2021
SG&A Expense (Quarterly) Benchmarks
Emergent BioSolutions Inc | 84.70M |
Creative Medical Technology Holdings Inc | 1.399M |
Viking Therapeutics Inc | 9.97M |
Stereotaxis Inc | 5.83M |
MAIA Biotechnology Inc | 2.660M |